Richard Henson is the Founder of PhageTech, Inc., a development stage firm that is developing novel technology for immunodiagnostics. He is a medical device executive with over 30 years of experience in medical device development and manufacturing.
In addition to running both public and private companies, he has served on the boards of Halo Healthcare, a breast cancer diagnostic company; ResVeRx, Inc. and TWAComm. He is also Chairman and board member of OCTANe Foundation, a member of the Dean’s Leadership Council at the UC Irvine School of Physical sciences and a member of the Chancellors CEO Roundtable at UC Irvine. He is the Co-Founder and former CEO of Source Scientific, LLC, a medical instrument and device development firm that was ranked in 2012 as one of the INC Magazine’s 5000 fastest growing companies in the US.
PhageTech’s breakthrough bioconductive technology creates a new category of biosensors for blood and urine testing that is portable, instant and mobile, eliminating central labs with their complexity and cost. A single sensor can deliver dozens of test results at once for infectious diseases, cancers and other biomarkers. Cloud-based hosting eliminates the outside lab and provides fast, inexpensive results for patients and caregivers. Based on a totally new approach to diagnostic testing, it’s unique patent position allows it to enter virtually any market and application. PhageTech will build a business developing and delivering these biosensors to healthcare companies world-wide.